Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common cause of cancer-specific death in men, according to the American Cancer Society. Approximately 70% of bladder tumors present as non-muscle invasive (NMI) disease and 10%-20% will progress to muscle invasion.
In patients with solitary distal ureteral stones, hydronephrosis is associated with prolonged stone clearance following shock wave lithotripsy (SWL), but the degree of hydronephrosis caused by the stones does not affect overall SWL outcome.
Age and maximal peak flow rate before tension-free vaginal tape (TVT) placement are independent risk factors for postoperative voiding dysfunction, a French study found.
Men who take finasteride or alpha blockers for BPH are at higher risk of prostate cancer than non-users, investigators in Finland conclude.
A 10-year follow-up study of patients with high-risk bladder cancer shows that mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) have similar effects on disease progression, need for subsequent treatment, and survival.
Contrary to what is commonly thought, the risk of having a positive repeat prostate biopsy is no lower for men with a fluctuating PSA level than it is for those with a steady or steadily increasing PSA level.
Photoselective vaporization of the prostate (PVP) for BPH provides outcomes similar to those of transurethral resection of the prostate (TURP).
Adding the alpha blocker doxazosin to standard treatment may help clear distal ureteral stones, according to researchers in Tashkent, Uzbekistan.
Sorafenib treatment doubles progression-free survival in patients with advanced renal cell carcinoma, regardless of whether they have received prior cytokine therapy.
Botulinum toxin type A (BTX-A) injections may be a promising treatment for BPH patients with urinary retention who are not candidates for surgery.
